Fairfax Financial Holdings Limited

Fairfax reported Q2 2026 net earnings of $1.4 billion and first-half net earnings of $2.1 billion. Operating income from insurance and reinsurance, adjusted to undiscounted basis and before risk margin, was $1.1 billion; underwriting income was $459 million versus $427 million in Q2 2025, and the combined ratio was 93.1% versus 93.3% a year ago. Interest and dividend income was $737 million, up 11% year over year from $660 million, while profits of associates were $43 million versus $131 million a year ago, and net investment gains were $769 million. Gross premium written was $9.4 billion, up 4.1% year over year. Book value per share ended at $1,304.39, up 4.8% from year-end 2025 adjusted for the $15 dividend. Management said consolidated investment return was 2%, fair value of securities above carrying value was $4.4 billion, and favorable reserve development was $152 million. For guidance, management did not provide formal next-quarter or full-year EPS guidance, but said associate income plus consolidated investments was running above the roughly $1 billion combined figure they had previously referenced. They also said interest and dividend income run rate is about 5%, and premium growth is being affected by softening market conditions, especially in North America.

Peter Clarke’s tone was confident but measured. He emphasized Fairfax’s decentralized model, discipline in a softening market, and the ability to shift toward higher-margin business rather than chase top-line growth. He also highlighted the company’s diversification by product and geography, especially the faster growth in international operations, and reiterated comfort with key transactions such as Kennedy-Wilson and the remaining Poseidon stake.

Amy Sherk focused on the quarter’s major transactions and balance sheet strength. She detailed the $838 million realized gain from selling 23.1% of Poseidon for $1.9 billion, the Kennedy-Wilson consolidation into Kona BidCo, and the expected closings for Andrew Peller, Sleep Number, IIFL Capital, and the Eurobank/Eurolife transactions. She said Fairfax held $2.3 billion of cash and investments at the holding company, had an undrawn $2 billion revolver, and that the pretax excess of fair value over carrying value for noninsurance associates and market-traded consolidated subsidiaries was $4.4 billion. She also noted common shareholders’ equity of $26 billion, book value per share of $1,304.39, and debt to total capital of 28% excluding noninsurance companies.

Analysts focused on softening pricing, the TRS sale, real-estate-linked exposure in the bond portfolio, associate income, leverage, float, and weather-related catastrophe risk. Management said softening remains most pronounced in North American property and may start to affect some casualty lines, but Fairfax is pulling back on less attractive business and benefiting from international growth. On the TRS, Peter Clarke said the partial sale did not reflect a lack of confidence in Fairfax stock, noting the company still bought back almost 1 million shares and retained a significant position. On leverage and float, management said debt issuances mostly replaced preferred shares with long-dated debt, and that float is a long-term compounding priority; on wildfires, they said there was nothing material in Q2 but they are watching closely for Q3.